• We investigated whether the use of ACEI/ARBs affects the clinical outcomes of primary breast cancer patients receiving taxane and anthracycline-based neoadjuvant chemotherapy. (jcancer.org)
  • In order to predict an oncologic outcome from locally advanced breast cancer patients who are treated with neoadjuvant chemotherapy with taxane-anthracycline based regimen, we can use pathologic complete response, an early response to neoadjuvant chemotherapy. (kjco.org)
  • By using integrated genomics, we identified a small number of overexpressed and amplified genes from chromosome 8q22 that were associated with early disease recurrence despite anthracycline-based adjuvant chemotherapy. (bioseek.eu)
  • Using integrated genomics, we identified a small number of over-expressed and amplified genes from chromosome 8q22 significantly associated with early disease recurrence despite anthracycline-based adjuvant chemotherapy. (bioseek.eu)
  • One example is a human study in which researchers discovered that higher levels of the antioxidant selenium in the blood of patients with aggressive B-cell non-Hodgkin's lymphoma correlated with increased achievable doses of anthracycline based chemotherapy, better treatment response, achievement of long term remission, and longer overall survival. (pinestreetfoundation.org)
  • In patients with limited disease, radiotherapy (RT) including new techniques (eg, proton and carbon ion beam RT) should be considered, particularly for unresectable primary tumors. (medscape.com)
  • Complete surgical resection of the tumor and preoperative radiotherapy and chemotherapies can be used for non-metastatic RPS. (biomedcentral.com)
  • This report describes a case of rapidly progressive retroperitoneal pleomorphic leiomyosarcoma that was favorably controlled by debulking surgery followed by combination chemotherapy and radiotherapy. (biomedcentral.com)
  • Approximately 50 Gy of radiotherapy was delivered to the remaining tumor. (biomedcentral.com)
  • Multimodal therapy with debulking surgery, combination chemotherapy and radiotherapy controlled a rapidly progressive retroperitoneal pleomorphic leiomyosarcoma. (biomedcentral.com)
  • Maintaining dose intensity of the chemotherapy and radiotherapy might contribute to overall tumor control. (biomedcentral.com)
  • Multimodal therapy incorporating surgery, radiotherapy, and chemotherapy is thus expected to improve survival in patients with RPS. (biomedcentral.com)
  • Preoperative radiotherapy was not administered because a large treatment volume could otherwise lead to late radiation-related damage of critical organs, such as the kidneys, liver and small bowel and because the patient required a therapeutic strategy that would produce more rapid relief of symptoms. (biomedcentral.com)
  • Main Outcomes and Measures: The main outcome was receipt of definitive treatment and proportion of purchased CC by treatment type (radical prostatectomy [RP], radiotherapy [RT], or active surveillance) and by distance to nearest VHA tertiary care facility. (bvsalud.org)
  • In addition to conventional radiotherapy, chemotherapy, and surgery, there are currently more and more popular neoadjuvant chemotherapy and molecular targeted therapies. (biomedcentral.com)
  • Radiotherapy and chemotherapy, as the routine treatment, face substantial challenges of resistance. (biomedcentral.com)
  • Combining some of these neoadjuvant approaches with standard-of-care chemotherapy or radiotherapy appears to "sensitize" tumor cells to treatment. (cancerbiomed.org)
  • Metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. (drugs.com)
  • Prior therapy should have included an anthracycline and a taxane in either the adjuvant or metastatic setting. (drugs.com)
  • Adjuvant chemotherapy for breast cancer after surgery has effectively lowered metastatic recurrence rates. (bioseek.eu)
  • However, a considerable proportion of women suffer recurrent cancer at distant metastatic sites despite adjuvant treatment. (bioseek.eu)
  • 11 ] demonstrated a substantial overall survival (OS) benefit in patients with PD-L1-positive (PD-L1 + ) metastatic or inoperable locally advanced TNBC through the addition of the anti-PD-L1 agent atezolizumab to first-line chemotherapy with nab-paclitaxel. (biomedcentral.com)
  • More effective treatments are needed for breast cancer that becomes locally advanced or metastatic. (roche.com)
  • An Open-label Randomized Phase II Study of Panitumumab Plus Oral Capecitabine and Infusional Oxaliplatin (XELOX) or XELOX alone for Second-line Treatment of Patients with Metastatic Clororectal Cancer. (trialstracker.net)
  • A Phase Ib/II, open label, multi-center, randomized study designed to assess the safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of immunotherapy-based treatment combinations in patients with locally advanced unresectable or metastatic G/GEJ cancer (hereafter referred to as gastric cancer) and esophageal cancer. (ucbraid.org)
  • Ewing sarcoma (ES) is a rare tumor and is usually treated with specific chemotherapy regimens. (medscape.com)
  • chemotherapy (see regimens below) prior to excision is not typically recommended but could be considered for periosteal lesions. (medscape.com)
  • Neoadjuvant chemotherapy (NAC) is one of the standard care regimens for patients with resectable early-stage breast cancer. (biomedcentral.com)
  • This is a Phase 1/2 study to assess the safety and efficacy of ELI-002 7P immunotherapy (a lipid-conjugated immune-stimulatory oligonucleotide [Amph-CpG-7909] plus a mixture of lipid-conjugated peptide-based antigens [Amph-Peptides 7P]) as adjuvant treatment in subjects with solid tumors with mutated KRAS/NRAS. (ucbraid.org)
  • Preclinical success has led to a profusion of clinical trials on LB100 adjuvant therapies, including a phase I trial in extensive-stage small-cell lung cancer, a phase I/II trial in myelodysplastic syndrome, a phase II trial in recurrent glioblastoma, and a completed phase I trial assessing the safety of LB100 and docetaxel in various relapsed solid tumors. (cancerbiomed.org)
  • Amplification of LAPTM4B and YWHAZ contributes to chemotherapy resistance and recurrence of breast cancer. (bioseek.eu)
  • EXPERT OPINION: Two randomized studies in early BCG failure disease demonstrate that single-agent Gem has superior efficacy versus repeated BCG therapy or mitomycin C. Studies enrolling patients with predominantly papillary disease without CIS, intermediate-risk (IR) disease, and less BCG exposure appear to derive the highest benefits from adjuvant Gem in terms of recurrence and progression. (bvsalud.org)
  • Docetaxel area under the curve (AUC) and maximum concentration (Cmax) in each cycle and total cumulative AUC (AUCcum) were calculated and related to the incidence of adverse effects and tumour recurrence. (unav.edu)
  • 4.5 mg*h/L was associated with tumour recurrence. (unav.edu)
  • Treatment of acute lymphoblastic leukemia (ALL) requires both systemically and locally directed therapies to prevent central nervous system (CNS) recurrence. (bvsalud.org)
  • [ 2 ] Under the WHO classification system, tumors are further classified as benign, intermediate or malignant. (medscape.com)
  • Soft tissue sarcomas (STS) are malignant tumors that arise from mesoderm-derived tissues, such as fat, muscle, and connective tissue. (biomedcentral.com)
  • However, not all patients respond to immunotherapy, acquired resistance remains a challenge, and responses are poor in certain tumors which are considered to be immunologically cold. (biomedcentral.com)
  • These new approaches are focused on patients with an inadequate response to current treatments, with emerging evidence of improved responses in various cancers with new immunotherapy agents, often in combinations with existing agents. (biomedcentral.com)
  • The phase III IMpassion130 trial comparing chemotherapy plus atezolizumab versus chemotherapy plus placebo brought breast cancer into the immunotherapy era. (biomedcentral.com)
  • The aim of our review is to present recent advances in TNBC treatment and to discuss open issues in order to better define potential future directions for immunotherapy in TNBC. (biomedcentral.com)
  • New and relevant evidence on the implementation of immune checkpoint-based treatments in TNBC has emerged over the last year, with the results of the IMpassion130 trial bringing breast cancer into the immunotherapy era. (biomedcentral.com)
  • Eligible patients will be randomized to chemotherapy or the combination of chemotherapy with checkpoint inhibitor immunotherapy. (ucbraid.org)
  • 1. Resistance of tumors to multiple chemotherapeutic agents is often due to the MDR (Multiple Drug Resistance) gene. (examyear.com)
  • Doxorubicin (Dox), a non-selective class I anthracycline antibiotic, is a potent chemotherapeutic agent which is used for the treatment of numerous cancers [ 1 ]. (oncotarget.com)
  • In 1949, nitrogen mustard (mechlorethamine) became the first chemotherapeutic agent approved by the U.S. Food & Drug Administration, which was rapidly followed by a wave of chemotherapy development 1 . (cancerbiomed.org)
  • The induced differential stress resistance results in improved resistance to cytotoxicity in normal cells, which, in turn, reduces cytotoxic side-effects due to chemotherapy, as well as improved effectiveness of chemotherapeutic agents. (justia.com)
  • Because chemotherapy affects cell division, both normal and cancerous cells are susceptible to the cytotoxic effects of chemotherapeutic agents. (justia.com)
  • Success of conventional chemotherapeutic regiment is based on the principle that tumors with high growth fractions (such as acute myelogenous leukemia and the lymphomas, including Hodgkin's disease) are more sensitive to chemotherapy because a larger proportion of the targeted cells are undergoing cell division at any given time. (justia.com)
  • It also has severe limitations on the dosage of chemotherapeutic agents that can be administered to a patient, thus, limiting the effective range of chemotherapy. (justia.com)
  • By making normal cells more resistant to chemotherapeutic agents, a patient's tolerance for cytotoxicity is improved, which, in turn, also improves the effectiveness of chemotherapy. (justia.com)
  • This TCEE also demonstrates antitumor properties such as the induction of cell cycle arrest and activation of apoptosis on human colon, lung, melanoma, osteosarcoma, and pancreatic cancer cells [ 16 - 19 ]. (hindawi.com)
  • Prospective Randomized Multicenter Phase II Trial to Investigate Intensified Neoadjuvant Chemotherapy in Locally Advanced Pancreatic Cancer Prospektive, randomisierte Phase-II Studie zur intensivie. (trialstracker.net)
  • Pharmacokinetic-guided (PKG) dosing has demonstrated beneficial effects in other tumors, but scarce data is available in pancreatic cancer. (unav.edu)
  • [ 6 ] Chemotherapy combinations, such as gemcitabine plus docetaxel and epirubicin plus interferon, have demonstrated possible efficacy. (medscape.com)
  • Itraconazole (ITZ) is a triazole anti-fungal treatment widely used in the prevention and systemic treatment of a broad range of fungal infections, including aspergillosis , blastomycosis , candidiasis , histoplasmosis , and in some dermatological and nail infections. (ecancer.org)
  • Most advanced and recurrent cases therefore will receive systemic chemotherapies as the alternative approach. (hindawi.com)
  • Additionally, a cohort of patients with esophageal cancer who have not received prior systemic treatment for their disease will be enrolled in this study. (ucbraid.org)
  • Modified FOLFIRINOX (mFOLFIRINOX) is a cornerstone in the systemic treatment of PDAC, including the neoadjuvant setting. (unav.edu)
  • PACCE: A Randomized, Open-Label, Controlled, Clinical Trial of Chemotherapy and Bevacizumab With and Without Panitumumab in the First-line Treatment of Subjects With A Phase 3 Clinical Trial Comparing Infusional 5 Fluorouracil, Leucovorin, and Oxaliplatin. (med-abstracts.com)
  • 5-Fluorouracil (5-FU) dosage was adjusted throughout neoadjuvant treatment according to pharmacokinetic parameters and Irinotecan (CPT-11) pharmacokinetic variables were retrospectively estimated. (unav.edu)
  • The treatment of recurrent osteosarcoma is primarily surgical in the case of isolated lung metastases, although stereotactic RT, radiofrequency ablation, or cryotherapy might be alternative options in patients unfit for surgery. (medscape.com)
  • A failure to respond to BCG vaccine may be defined as persistent or recurrent tumor when a BCG vaccine reaction is evident. (medscape.com)
  • Generally, tumor size and axillary lymph node metastasis status are the most important prognostic factors for breast cancer patients. (kjco.org)
  • Sphingolipids are modified in multiple cancers and are responsible for tumor proliferation, progression, and metastasis. (frontiersin.org)
  • Thus, angiogenesis is a necessary and required step for transition from a small harmless cluster of cells to a large tumour and is also required for the spread of a tumour, invasion and/or metastasis. (biomedcentral.com)
  • Identification of the genes crucial for tumor response to specific chemotherapy drugs is a challenge but is necessary to improve outcomes. (bioseek.eu)
  • Current trials employ 3-6 cycles of initial combination chemotherapy after biopsy, followed by local therapy, and another 6-10 cycles of chemotherapy, usually given at 2- to 3-week intervals. (medscape.com)
  • When a combination of papillary tumor and CIS is present, the papillary tumor is removed before treatment of the CIS is initiated. (medscape.com)
  • The aim of this study is to evaluate the prognostic factors of the group who received neoadjuvant chemotherapy with a taxane-anthracycline combination regimen. (kjco.org)
  • We retrospectively analyzed for locally advanced breast cancer patients who received neoadjuvant chemotherapy with adjuvant extension with taxane-anthracycline combination regimen. (kjco.org)
  • In contrast, the antitumor effects and related biological mechanism of TCEE as well as the combination drug effects with conventional chemotherapy agents remain unclear particularly in human hepatocellular carcinoma cells. (hindawi.com)
  • Sphingolipid-targeting drugs have been tested alone or in combination with chemotherapy, exhibiting antitumor activity alone and in synergism with chemotherapy in vitro and in vivo . (frontiersin.org)
  • In this article, we turn our focus to lymphoma, conducting a systematic search for published research that would support or discourage the use of antioxidants in combination with chemotherapy. (pinestreetfoundation.org)
  • Multicenter, explorative phase II study of perioperative 5-FU, leucovorin, docetaxel, and oxaliplatin (FLOT) in combination with Trastuzumab in patients with HER2-positive, locally advanced resectable. (trialstracker.net)
  • Table 1 summarises the results from phase II trials utilizing bevacizumab in combination with chemotherapy, many of which are still preliminary. (biomedcentral.com)
  • Participants who experience loss of clinical benefit or unacceptable toxicity during Stage 1 may be eligible to receive treatment with a different treatment combination (Stage 2). (ucbraid.org)
  • When a Stage 2 treatment combination is available, this will be introduced by amending the protocol. (ucbraid.org)
  • CONCLUSION: A short course of Elo-KRd induction followed by Elo-lenalidomide maintenance demonstrated activity in predominantly lenalidomide-refractory and / or high-risk MM. The results with this well-tolerated combination are comparable to other contemporary approved triplet combinations. (bvsalud.org)
  • SCLC is a neuroendocrine carcinoma that exhibits aggressive behavior, rapid growth, early spread to distant sites, exquisite sensitivity to chemotherapy and radiation, and frequent association with distinct paraneoplastic syndromes, including hypercalcemia, Eaton-lambert syndrome, syndrome of inappropriate diuretic hormone, and many others. (medscape.com)
  • EVINEC: Safety and Tolerability of Everolimus as second-line treatment in poorly differentiated neuroendocrine carcinoma / neuroendocrine carcinoma G3 according to WHO 2010 and neuroendocrine tumor G3. (trialstracker.net)
  • The laparoscopic approach for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (L-CRS + HIPEC) in highly selected patients was previously reported from the PSOGI registry with a demonstrable reduction in length of stay and post-operative morbidity. (unav.edu)
  • Many studies have reported that there are no differences in the oncologic outcomes between NC and adjuvant chemotherapy [ 2 ]. (kjco.org)
  • Endoscopic surgery, which is the initial treatment of papillary cancers, is not effective for CIS because the disease is often so diffuse and difficult to visualize that surgical removal is not feasible. (medscape.com)
  • Clinical trials have shown that patients with prostate, lung, and basal cell carcinoma have benefited from treatment with itraconazole, and there are additional reports of activity in leukaemia, ovarian, breast, and pancreatic cancers. (ecancer.org)
  • Although PP2A has historically been identified as a tumor suppressor, inhibition of PP2A has paradoxically demonstrated potential as a therapeutic target for various cancers. (cancerbiomed.org)
  • No evidence suggests that these adjuvant therapies are as effective as bacillus Calmette-Guérin (BCG). (medscape.com)
  • No patient discontinued (223)Ra because of treatment toxicity. (researchgate.net)
  • The study is designed with the flexibility to open new treatment arms as new treatments become available, close existing treatment arms that demonstrate minimal clinical activity or unacceptable toxicity, modify the participant population, or introduce additional cohorts of participants with other types of advanced primary liver cancer. (ucbraid.org)
  • One third of the patients had at least 1 dose reduction of docetaxel due to toxicity. (unav.edu)
  • Conclusion: We report for the first time a relation between docetaxel exposure and toxicity and recommend specific targets of drug exposure with implications for the clinical management of early breast cancer patients. (unav.edu)
  • For patients with advanced non-small cell lung cancer (NSCLC) harboring the ALK gene rearrangement, ceritinib (Zykadia) provided longer progression-free survival than chemotherapy in patients previously treated with chemotherapy and crizotinib (Xalkori), but gastrointestinal toxicity was. (ascopost.com)
  • No differences in pCR and survival outcomes were seen between ACEI/ARB users and non-users among breast cancer patients receiving neoadjuvant chemotherapy. (jcancer.org)
  • The 5 year disease-free survival (DFS) per tumor origin was: 94% for PMP-LG, 85% for PMP-HG, 100% for benign multicyst peritoneal mesothelioma (MPM), 37.4% for colonic origin, and 54%(at 3 years) for ovarian origin. (unav.edu)
  • Conclusions: Pharmacokinetically-guided dose adjustment of standard chemotherapy treatments might improve survival outcomes in patients with pancreatic ductal adenocarcinoma. (unav.edu)
  • The follow-up time of breast cancer data with diagnosis in 2019 in the SEER database is less than two years, this study also used 1-year survival as the study outcome, to establish a predictive model to identify people with better and worse prognosis, especially people with a poorer prognosis, and to assist physicians in taking the best interventional treatment for patients promptly. (biomedcentral.com)
  • Treatment of patients with extraskeletal ES follows the same principles as treatment for bone ES and incorporates chemotherapy in all cases, as well as postoperative RT in most cases. (medscape.com)
  • Low-grade intramedullary and surface osteosarcoma and periosteal sarcomas with pathological findings of high-grade disease - The NCCN recommends postoperative chemotherapy. (medscape.com)
  • 2. Comparison of safety and efficacy of Gem according to risk category, type of tumor (papillary vs. carcinoma in situ (CIS)), and tumor grades. (bvsalud.org)
  • This phase II study combined elotuzumab (Elo) with carfilzomib, lenalidomide, and dexamethasone (KRd) for treatment of MM in first relapse with the aim of improving efficacy. (bvsalud.org)
  • ACE inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) may have anti-tumor properties. (jcancer.org)
  • There is a growing body of evidence to suggest that ACEIs might have anti-tumor properties[ 2 , 3 ]. (jcancer.org)
  • Findings of other lesions indicates a non-bone primary tumor. (medscape.com)
  • Approximately 60% of the enrolled patients (451 for each treatment arm) experienced relapse after prior adjuvant/neoadjuvant treatment, while 37% presented with de novo stage IV disease. (biomedcentral.com)
  • 40 mg/m 2 on day 1 and 30 mg/m 2 on day 8 every 28 days (as part of the VCAP-AMP-VECP multiagent chemotherapy regimen) for 6 cycles (Tsukasaki 2007). (medilib.ir)
  • Results: Docetaxel clearance showed no change over the 4 treatment cycles, but a gradual increase in the volume of distribution was observed. (unav.edu)
  • METHODS: Enrolled patients received Elo-KRd induction for 4 cycles, and Elo-lenalidomide maintenance until progression. (bvsalud.org)
  • ESMO-PaedCan-EURACAN guidelines recommend specifying the tumor type and subtype according to the 2013 World Health Organization (WHO) classification. (medscape.com)
  • Given the lack of effective treatments in this subtype of breast cancer, several efforts have been conducted in recent years to increase the therapeutic opportunities for TNBC patients. (biomedcentral.com)
  • Treatment of bladder CIS differs from that of papillary transitional cell carcinoma (TCC). (medscape.com)
  • 2000) A second study, involving the chemotherapy drugs etoposide and calcimycin, confirms this finding: Human Burkitt's lymphoma cells were unable to die quickly by apoptosis in the presence of oxidative stress and instead died using the slower and messier method of necrosis. (pinestreetfoundation.org)
  • Neoadjuvant chemotherapy (NC) is a standard therapy for locally advanced breast cancer patients [ 1 ]. (kjco.org)
  • Therefore, it would be advantageous to identify patients with chemosensitive tumors before initiating NAC, to avoid potential therapy-related complications and an inappropriate delay of surgical treatment. (biomedcentral.com)
  • The development of alternative or adjuvant treatments to improve the clinical outcome of the conventional therapy for liver cancer is therefore in urgent need. (hindawi.com)
  • Successful TIL therapy starts with the identification, enrichment, stimulation, and expansion of potent tumor-reactive T cells. (biomedcentral.com)
  • In clinical practice, a key challenge for generating TIL products is the accessibility, quantity, and quality of tumor tissue in the era of neo-adjuvant therapy. (biomedcentral.com)
  • Indications for single-agent therapy, preferred second-line therapy, subsequent therapy, relapsed or refractory therapy, pediatric and adult treatment, and limitations of use are all addressed within each section of specific cancer. (ibx.com)
  • Negative regulation of protein phosphatase 2A (PP2A) as an adjuvant therapy has demonstrated such chemo- and radio-sensitizing effects 4 . (cancerbiomed.org)
  • Consequently, endocrine therapy, including tamoxifen or aromatase inhibitors (AIs), has become an effective treatment for these patients. (spandidos-publications.com)
  • The mainstay of adjuvant treatment for early-stage, hormone receptor-positive breast cancer has been endocrine therapy, either with tamoxifen and. (ascopost.com)
  • The objective of this review was to analyze the results from preclinical and clinical trials of these drugs for the treatment of cancer. (frontiersin.org)
  • Also, see the Clinical Presentations of Lung Cancer: Slideshow and Lung Cancer Staging -- Radiologic Options slideshows for additional information on SCLC staging and treatment. (medscape.com)
  • It was structured in 5 sections: general information and clinical practice, knowledge of clinical trials, diagnosis work-up and nodal marking, axillary staging, and axillary treatment. (unav.edu)
  • We describe existing clinical trials of antiangiogenic agents and the challenges facing the clinical development and optimal use of these agents for the treatment of breast cancer. (biomedcentral.com)
  • This review focusses on clinical aspects of treatment of breast cancer with monoclonal antibodies, and tyrosine kinase and mammalian target of rapamycin (mTOR) inhibitors. (biomedcentral.com)
  • Another method of the invention comprises administering a cell growth inhibitor to the subject and administering to the subject a chemotherapy agent. (justia.com)
  • Adverse prognostic or predictive factors include detectable primary metastases, axial or proximal extremity tumor site, large tumor size, elevated serum alkaline phosphatase or lactate dehydrogenase levels, and older age. (medscape.com)
  • When the NC is performed, tumors and axillary lymph nodes are down staged, resulting in the loss of traditional prognostic factors [ 6 ]. (kjco.org)
  • Other prognostic factors are required for making a difference from adjuvant chemotherapy. (kjco.org)
  • Eralp Y, Aydıner A,Kizir A,Kaytan E,Oral EN,Topuz E, "Resectable thymoma: treatment outcome and prognostic factors in the late adolescent and adult age group," Cancer Investigation 21(5),737-43 (2003). (yesimeralp.com)
  • However, despite the lack of large-scale randomized controlled studies with single-agent intravesical gemcitabine (Gem), it has emerged as a popular salvage agent after BCG failure or even a treatment alternative to BCG. (bvsalud.org)
  • Characterization of treatment regimen details pertaining to single-agent intravesical adjuvant Gem use among disease states of NMIBC characterized by risk and BCG exposure. (bvsalud.org)
  • As a consequence of treatments, the most frequent mechanism of cell death is apoptosis, followed by autophagy. (frontiersin.org)
  • Of note, an increased carbohydrate uptake and/or induction of death receptors of cancer cells was exploited to develop glycoconjugates that potentially induce cellular stress, ROS and apoptosis. (degruyter.com)
  • The authors of the above-mentioned study on Burkitt lymphoma cells and chemotherapy suggest that including antioxidants in the treatment protocol may enhance chemotherapy-induced apoptosis and phagocytosis. (pinestreetfoundation.org)
  • Weinberg characterized "aberrant metabolic phenotype" with "autologous proliferation signaling, apoptosis resistance, evasion of proliferation inhibition, continuous angiogenesis, infiltration and migration, unlimited replication capacity, immune escape" in tumor cells. (biomedcentral.com)
  • CC-486 priming contributed to the reprograming of the tumor microenvironment by upregulation of genes related to apoptosis (P (bvsalud.org)
  • If confirmed by further study, genotyping for CYP19A1 rs1008805 polymorphism may provide predictive information to improve the selection of endocrine treatment. (spandidos-publications.com)
  • For decades, 5-year tamoxifen administration was the gold standard for the adjuvant endocrine treatment of breast cancer ( 9 ). (spandidos-publications.com)
  • Many research studies, encompassing cell culture tests in the laboratory and also animal and some human studies, are coming to a conclusion often very different from the conventional perspective that chemotherapy and antioxidants should never be combined. (pinestreetfoundation.org)
  • Radiofrequency ablation and stereotactic RT are potential alternative local treatment options for primary lung or bone metastases. (medscape.com)
  • The alpha-emitter radium-223 ((223)Ra) is a bone-seeking radionuclide studied as a new treatment for patients with bone metastases from hormone-refractory prostate cancer. (researchgate.net)
  • Bicarbonate Increases Tumor pH and Inhibits Spontaneous Metastases. (kreftfri.no)
  • Moreover, treatment with TCEE is found to enhance the cytotoxic effects of amphotericin B in human colon cancer cell both in vitro and in vivo [ 17 ]. (hindawi.com)
  • Doxorubicin (Dox) is a cytotoxic drug widely incorporated in various chemotherapy protocols. (oncotarget.com)
  • In addition, a deeper characterization of immune infiltrates, including the presence of a high number of cytotoxic (CD8 + ) TILs or a high CD8 + /FOXP3 + ratio, is able to define TNBC patients with a better prognosis following neoadjuvant chemotherapy [ 6 ]. (biomedcentral.com)
  • Actually, the entire metabolic network reprograms under the control of oncogenes and tumor suppressor genes, and the flow of nutrient in metabolic networks is also redefined in the process of tumorigenesis. (biomedcentral.com)
  • Complete surgical excision, where feasible, rather than RT alone, is regarded as the best modality for local tumor control. (medscape.com)
  • NCCN guidelines recommend that the final pathologic evaluation include assessment of surgical margins as well as the size/dimensions of tumors. (medscape.com)
  • Surgical resection for the purpose of tumor debulking was then performed. (biomedcentral.com)
  • After curative surgery, adjuvant chemotherapy with the same regimen was performed. (kjco.org)
  • [ 1 ] ESMO-PaedCan-EURACAN recommends surgery alone for low-grade parosteal osteosarcomas, and finds no benefit for chemotherapy for periosteal lesions. (medscape.com)
  • Debulking surgery could be performed, but the small residual tumor had rapidly grown to an approximately 22 cm in length on the major axis within 38 days after the operation. (biomedcentral.com)
  • SiRNA-mediated knockdown of either of two of these genes, the antiapoptotic gene YWHAZ and a lysosomal gene LAPTM4B, sensitized tumor cells to anthracyclines, and overexpression of either of the genes induced anthracycline resistance. (bioseek.eu)
  • Two of these genes, the anti-apoptotic gene YWHAZ , and LAPTM4B , a novel lysosomal gene, sensitized tumor cells to anthracyclines when either was depleted by siRNA knockdown and induced drug resistance when either was over-expressed. (bioseek.eu)
  • Overexpression of these two genes may predict anthracycline resistance and influence selection of chemotherapy. (bioseek.eu)
  • The overwhelming majority of studies find a favorable interaction between antioxidants and chemotherapy, providing evidence that antioxidants can decrease chemotherapy side effects, increase treatment effectiveness, and decrease resistance to chemotherapy. (pinestreetfoundation.org)
  • The aberrant glucose metabolism is associated with dramatically increased bioenergetics, biosynthetic, and redox demands, which is vital to maintain rapid cell proliferation, tumor progression, and resistance to chemotherapy and radiation. (biomedcentral.com)
  • This review summarizes recent progress in our understanding of glucose metabolism in chemo- and radio-resistance malignancy, and highlights potential molecular targets and their inhibitors for cancer treatment. (biomedcentral.com)
  • Among many reasons, the treatment resistance is the one of major drawbacks. (biomedcentral.com)
  • Herein, this review updates the mechanisms of metabolic reprogramming involved in tumor chemo- and radio-resistance. (biomedcentral.com)
  • In particular, the present invention provides methods for enhancing the effectiveness of chemotherapy by inducing differential stress resistance in normal cells and cancer cells via short-term starvation, cell growth inhibitors, or reduced caloric or glucose intake. (justia.com)
  • In another aspect, the invention features methods of contacting a cancer cell with a chemotherapy agent and methods of increasing resistance of a non-cancer cell to a chemotherapy agent. (justia.com)
  • One is the ability to administer large numbers of highly selected cells with high avidity for tumor antigens that can recognize shared and patient-specific mutated (neo) antigens. (biomedcentral.com)
  • Sensitivity of the tumor to chemotherapy are predictable and NC treats micrometastasis earlier. (kjco.org)